Abstract：Objective: To evaluate the association of serum adiponectin concentration with breast cancer risk in Chinese Han women. Methods：Related papers about the association of serum adiponectin concentration with breast cancer risk in Chinese Han women published between 1995 and 2012 were retrieved and evaluated. Data were reanalyzed by Meta analysis. Results：A total of eight studies that meet the inclusion／exclusion criteria were included. Data from 481 cases of breast cancer and 346 healthy control subjects were analyzed. The results showed,① Patients with breast cancer had lower serum adiponectin values than healthy controls(P<0.05, WMD=-2.412,95％CI-3.173 to-1.651). Among premenopausal women, patients with breast cancer also had lower serum adiponectin values than healthy controls(P<0.05,WMD=-1.884,95％CI-2.770 to-0.998).② Compared with patients without lymph node metastasis, patients with lymph node metastasis had significantly lower serum adiponectin levels(P=0.002,WMD=-1.981,95％CI-3.238 to-0.724). Conclusion: Lower adiponectin concentration could be a risk factor of breast cancer and a predictor of poor prognosis.
［1］ Miyoshi Y, Funahashi T, Kihara S, et al. Association of serum adiponectin levels with breast cancer risk［J］. Clin Cancer Res, 2003, 9(15):5699-5704.［2］ Chen DC, Chung YF, Yeh YT, et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients ［J］. Cancer Lett, 2006, 237(1):109-114.［3］ 严艺,陈雄雁,林还转, 等.乳腺癌患者血清adiponectin水平变化及其临床意义［J］. 中国医学检验杂志, 2006, 7(3):151-152.［4］ 许聿新.脂联素及代谢综合征与乳腺癌关系的临床研究［D］.济南:山东大学,2006.［5］ 杨莉萍,侯 敢. 乳腺癌患者手术前后Lp(a)、adiponectin 和 TNF-α水平观察与分析［J］. 宁夏医学杂志, 2006, 28(9):676-677.［6］ 韩英娥,张恩,曹伟. 乳腺癌患者血清脂联素检测的临床意义［J］. 陕西医学杂志, 2007, 36(10):1381-1383.［7］ 李元栋.女性乳腺癌患者脂联素血清水平及意义［D］. 太原:山西医科大学,2007.［8］ 崔红霞.脂联素及脂联素基因多态性与乳腺癌发病风险的相关性研究［D］. 太原:山西医科大学,2009.［9］ 范杰, 刘冰, 曹文艳, 等.乳腺癌患者血清抵抗素、脂联素和瘦素水平及其临床意义［J］. 检验医学, 2011, 26(1):36-39.［10］ 张家鑫,马忠兵,于理想, 等.血清脂联素、瘦素水平与乳腺癌相关性的初步研究［J］. 山东大学学报:医学版, 2012,50(6):110-113.［11］ Xu XT, Xu Q, Tong JL, et al. Metaanalysis: circulating adiponectin levels and risk of colorectal cancer and adenoma［J］. J Dig Dis, 2011, 12(4):234-244.［12］ Kang JH, Yu BY, Youn DS. Relationship of serum adiponectin and resistin levels with breast cancer risk［J］. J Korean Med Sci, 2007, 22(1):117-121.［13］ Wang Y, Lam KS, Xu A. Adiponectin as a negative regulator in obesity-related mammary carcinogenesis［J］. Cell Res, 2007, 17(4):280-282.［14］ Jarde T, Caldefie-Chezet F, Goncalves-Mendes N, et al. Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies［J］. Cancer Res, 2008, 68(9):3178-3184.［15］ Dos Santos E, Benaitreau D, Dieudonne MN, et al. Adiponectin mediates an antiproliferative response in human MDA-MB 231 breast cancer cells ［J］. Oncol Rep, 2008, 20(4):971-977.［16］ Braenhielm E, Veitonmaki N, Cao R, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis［J］. Proc Natl Acad Sci U S A, 2004, 101(8):2476-2481.
2013, Vol. 23 
